Close Menu

RNA-seq

A New York Genome Consortium-led team plans retrospective and prospective analyses on very rare cancers in the hopes of improving treatment options available for patients.

Using samples from heart failure patients and healthy controls, researchers uncovered a gene that, when absent in mice, reduced their risk of heart failure.

In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.

APEX-seq builds on a proteomic labelling technique and offers a new spatial genomics tool for looking at the life of transcripts within the cell.

Combined DNA/RNA-seq efforts in various settings could lead to new ways of treating kids with drugs meant for adults or to the development of new therapies.

With RNA sequence data on thousands of individual lung cells, researchers fleshed out new and known cell clusters, before digging into cell state and cellular interaction changes in asthma.

In Genome Biology this week: study of 'dark' genome regions, algorithm to determine DNA methylation variation, and more.

Most individuals had at least one tissue, of the 29 studied, containing clonal mutations, some of which are typically found in cancer cells.

In patients with a range of rare diseases, RNA sequencing in blood had a 7.5 percent diagnostic rate and identified candidate genes in 16.7 percent of cases.

The team evaluated various technologies in an attempt to develop a framework to compare future methods against and to serve as a guide for researchers. 

Pages

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.